{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T14:40:09Z","timestamp":1784385609410,"version":"3.55.0"},"reference-count":14,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lungcancerjournal.info","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.lungcan.2016.07.001","type":"journal-article","created":{"date-parts":[[2016,7,6]],"date-time":"2016-07-06T00:29:27Z","timestamp":1467764967000},"page":"148-150","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"special_numbering":"C","title":["Immune-related pancreatitis secondary to nivolumab in a patient with recurrent lung adenocarcinoma: A case report"],"prefix":"10.1016","volume":"99","author":[{"given":"Kazuhiko","family":"Ikeuchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5743-0149","authenticated-orcid":false,"given":"Yusuke","family":"Okuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taku","family":"Tabata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2016.07.001_bib0005","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1200\/JCO.2015.63.8049","article-title":"Pointed progress in second-Line advanced non-Small-Cell lung cancer: the rapidly evolving field of checkpoint inhibition","volume":"34","author":"Melosky","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2016.07.001_bib0010","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2016.07.001_bib0015","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2016.07.001_bib0020","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/annonc\/mdv623","article-title":"Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper","volume":"27","author":"Champiat","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2016.07.001_bib0025","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1158\/1078-0432.CCR-15-1136","article-title":"Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes","volume":"22","author":"Freeman-Keller","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2016.07.001_bib0030","first-page":"180","article-title":"Opdivo (Nivolumab): second PD-1 inhibitor receives FDA approval for unresectable or metastatic melanoma","volume":"8","author":"Raedler","year":"2015","journal-title":"Am. Health Drug Benefits"},{"key":"10.1016\/j.lungcan.2016.07.001_bib0035","doi-asserted-by":"crossref","first-page":"652","DOI":"10.2337\/diabetes.48.3.652","article-title":"Prevention of autoimmune recurrence and rejection by adenovirus-mediated CTLA4Ig gene transfer to the pancreatic graft in BB rat","volume":"48","author":"Uchikoshi","year":"1999","journal-title":"Diabetes"},{"key":"10.1016\/j.lungcan.2016.07.001_bib0040","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1007\/s00262-008-0642-y","article-title":"Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases","volume":"58","author":"Di Giacomo","year":"2009","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.lungcan.2016.07.001_bib0045","doi-asserted-by":"crossref","first-page":"e528","DOI":"10.1097\/RLU.0000000000000940","article-title":"Pancreatitis secondary to anti-programmed death receptor 1 immunotherapy diagnosed by FDG PET\/CT","volume":"40","author":"Alabed","year":"2015","journal-title":"Clin. Nucl. Med."},{"key":"10.1016\/j.lungcan.2016.07.001_bib0050","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ejca.2016.02.025","article-title":"Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy","volume":"60","author":"Hofmann","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.lungcan.2016.07.001_bib0055","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.2214\/ajr.170.5.9574610","article-title":"Autoimmune pancreatitis: CT and MR characteristics","volume":"170","author":"Irie","year":"1998","journal-title":"AJR Am. J. Roentgenol."},{"key":"10.1016\/j.lungcan.2016.07.001_bib0060","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ctrv.2016.02.001","article-title":"Management of toxicities of immune checkpoint inhibitors","volume":"44","author":"Spain","year":"2016","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.lungcan.2016.07.001_bib0065","unstructured":"Administration USFaD. OPDIVO (nivolumab9 Injection label) http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/125554lbl.pdf."},{"key":"10.1016\/j.lungcan.2016.07.001_bib0070","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ctrv.2016.02.003","article-title":"Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy","volume":"45","author":"Eigentler","year":"2016","journal-title":"Cancer Treat. Rev."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500216303968?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500216303968?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,10]],"date-time":"2018-09-10T14:21:15Z","timestamp":1536589275000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500216303968"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":14,"alternative-id":["S0169500216303968"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2016.07.001","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune-related pancreatitis secondary to nivolumab in a patient with recurrent lung adenocarcinoma: A case report","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2016.07.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}